CO6270339A2 - Formulaciones de vacuna meningococica - Google Patents

Formulaciones de vacuna meningococica

Info

Publication number
CO6270339A2
CO6270339A2 CO10052816A CO10052816A CO6270339A2 CO 6270339 A2 CO6270339 A2 CO 6270339A2 CO 10052816 A CO10052816 A CO 10052816A CO 10052816 A CO10052816 A CO 10052816A CO 6270339 A2 CO6270339 A2 CO 6270339A2
Authority
CO
Colombia
Prior art keywords
meningococic
meningitidis
vaccine formulations
lyophilised
formulation
Prior art date
Application number
CO10052816A
Other languages
English (en)
Spanish (es)
Inventor
Mario Contorni
Jina Kazzaz
Derek Ohagan
Manmohan Singh
Mildred Ugozzoli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6270339A2 publication Critical patent/CO6270339A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CO10052816A 2007-10-19 2010-05-04 Formulaciones de vacuna meningococica CO6270339A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99959007P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CO6270339A2 true CO6270339A2 (es) 2011-04-20

Family

ID=40428348

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10052816A CO6270339A2 (es) 2007-10-19 2010-05-04 Formulaciones de vacuna meningococica

Country Status (20)

Country Link
US (2) US20100285069A1 (https=)
EP (2) EP2462949A3 (https=)
JP (3) JP5701058B2 (https=)
CN (1) CN101951949B (https=)
AT (1) ATE553774T1 (https=)
AU (1) AU2008313424B2 (https=)
BR (2) BRPI0818545A2 (https=)
CA (2) CA2925217A1 (https=)
CO (1) CO6270339A2 (https=)
CY (1) CY1112908T1 (https=)
DK (1) DK2200642T3 (https=)
ES (1) ES2383231T3 (https=)
HR (1) HRP20120433T1 (https=)
MX (2) MX2010004271A (https=)
NZ (1) NZ584683A (https=)
PL (1) PL2200642T3 (https=)
PT (1) PT2200642E (https=)
RU (2) RU2498815C2 (https=)
SI (1) SI2200642T1 (https=)
WO (1) WO2009050586A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
JP2012512240A (ja) * 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
KR101594228B1 (ko) * 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
IN2012MU00206A (https=) * 2012-01-20 2013-08-09
MX346678B (es) 2012-03-07 2017-03-29 Novartis Ag Sales de arginina utiles inmunologicamente.
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102906912B1 (ko) 2016-09-02 2026-01-05 사노피 파스퇴르 인크 네이세리아 메닌기티디스 백신
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2019083865A1 (en) * 2017-10-25 2019-05-02 Merck Sharp & Dohme Corp. VACCINES WITH ADJUVANT
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
PL175595B1 (pl) 1992-08-31 1999-01-29 North American Vaccine Inc Antygenowy/immunogenny koniugat do wytwarzania szczepionki przeciwko infekcji N.meningitidis, sposób wytwarzania antygenowego/immunogennego koniugatu oraz szczepionka przeciwko infekcji N.meningitidis
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
WO1998053851A1 (en) 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0991761B1 (en) 1997-08-21 2008-01-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
PT1053325E (pt) * 1998-02-05 2006-05-31 Glaxosmithkline Biolog Sa Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
BR9910749A (pt) * 1998-05-29 2001-02-13 Chiron Corp Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
EP1741443B1 (en) * 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
JP2004505885A (ja) 1998-08-19 2004-02-26 ノース　アメリカン　ワクチン，　インコーポレイテッド Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
BR9914374A (pt) 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
OA12590A (en) 2001-01-23 2006-06-08 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine.
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
PT1777236T (pt) 2002-03-26 2017-02-13 Glaxosmithkline Biologicals Sa Sacáridos modificados possuindo estabilidade melhorada em água para utilização como um medicamento
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
EP1524991A1 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
JP2006502228A (ja) * 2002-10-07 2006-01-19 カイロン コーポレイション Ｈｉｖワクチン処方物
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
EP1562982B1 (en) * 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CN103357002A (zh) * 2003-10-02 2013-10-23 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
EP1706481A2 (en) * 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Vaccine
AU2005230708B2 (en) 2004-04-05 2009-01-15 Zoetis Services Llc Microfluidized oil-in-water emulsions and vaccine compositions
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2434029T3 (es) * 2004-11-15 2013-12-13 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas que contiene antígeno de antrax, micropartículas de polímero biodegradable, y adyuvante inmunológico que contiene polinucleótido
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
PT1861120T (pt) * 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8156755B2 (en) * 2005-06-03 2012-04-17 Intervet International B.V. Refrigerator for storing vials and cartridge for use in the same
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
WO2007100699A2 (en) * 2006-02-24 2007-09-07 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines

Also Published As

Publication number Publication date
JP5701058B2 (ja) 2015-04-15
JP2011500662A (ja) 2011-01-06
PL2200642T3 (pl) 2012-09-28
RU2013133864A (ru) 2015-01-27
HRP20120433T1 (en) 2012-07-31
ES2383231T3 (es) 2012-06-19
JP2016029108A (ja) 2016-03-03
AU2008313424A1 (en) 2009-04-23
EP2462949A3 (en) 2012-09-05
WO2009050586A1 (en) 2009-04-23
SI2200642T1 (sl) 2012-06-29
AU2008313424B2 (en) 2014-05-22
CY1112908T1 (el) 2016-04-13
MX2010004271A (es) 2010-05-03
CN101951949A (zh) 2011-01-19
NZ584683A (en) 2012-05-25
JP2013216704A (ja) 2013-10-24
CN101951949B (zh) 2013-10-02
MX340096B (es) 2016-06-27
EP2200642A1 (en) 2010-06-30
CA2925217A1 (en) 2009-04-23
CA2702871A1 (en) 2009-04-23
JP5925736B2 (ja) 2016-05-25
EP2462949A2 (en) 2012-06-13
BR122016015627A2 (pt) 2018-10-30
US20160228529A1 (en) 2016-08-11
EP2200642B1 (en) 2012-04-18
PT2200642E (pt) 2012-05-30
RU2498815C2 (ru) 2013-11-20
RU2010119947A (ru) 2011-11-27
ATE553774T1 (de) 2012-05-15
US20100285069A1 (en) 2010-11-11
BRPI0818545A2 (pt) 2017-07-04
DK2200642T3 (da) 2012-07-16

Similar Documents

Publication Publication Date Title
CO6270339A2 (es) Formulaciones de vacuna meningococica
MX348734B (es) Vacunacion multiple que incluye meningococcus del serogrupo c.
RU2378009C2 (ru) Иммунизация против менингококков серогруппы y с помощью белков
CR10123A (es) Vacuna.
CY1110140T1 (el) Εμβολιασμος με μηνιγγοκοκκικο συζευγμα
MXPA05007886A (es) Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo.
CY1111814T1 (el) Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων
Centers for Disease Control and Prevention (CDC Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005
DK1755662T3 (da) Kombinerede meningokokkonjugater med fælles bærerprotein
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
WO2018042017A3 (en) Vaccines for neisseria gonorrhoeae
Block et al. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination
MX2015013401A (es) Procedimiento de tratamiento.
Haneberg et al. Can nonliving nasal vaccines be made to work?
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
AR095579A1 (es) Procedimiento de inmunización

Legal Events

Date Code Title Description
FC Application refused